减少针对2型炎症的生物制剂剂量的策略:系统综述。

IF 4.6 2区 医学 Q1 ALLERGY
Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso
{"title":"减少针对2型炎症的生物制剂剂量的策略:系统综述。","authors":"Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso","doi":"10.1007/s11882-025-01214-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.</p><p><strong>Recent findings: </strong>Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"32"},"PeriodicalIF":4.6000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review.\",\"authors\":\"Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso\",\"doi\":\"10.1007/s11882-025-01214-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.</p><p><strong>Recent findings: </strong>Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.</p>\",\"PeriodicalId\":55198,\"journal\":{\"name\":\"Current Allergy and Asthma Reports\",\"volume\":\"25 1\",\"pages\":\"32\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Allergy and Asthma Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11882-025-01214-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-025-01214-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:本综述评价了抗2型生物制剂在慢性炎症性疾病中减量治疗的现有证据。鉴于需要长期治疗,在不影响疗效的情况下优化剂量对于可持续的疾病管理至关重要。最近的研究发现:生物剂量减少策略,如逐渐减少、降级、剂量间隔和间隔剂量延长,越来越多地在各种2型炎症疾病中被探索,特别是在现实生活中。研究显示不同的结果取决于疾病类型、患者特征和减径方法。19项研究符合本系统综述的纳入标准。证据支持剂量逐渐减少的可行性,特别是对于dupilumab,在维持疾病控制的同时减少药物暴露。然而,标准化的减量方案和明确的患者选择标准仍然缺乏。需要进一步的前瞻性对照研究来确定最佳、安全和个性化的2型炎症性疾病的长期治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review.

Purpose of review: This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.

Recent findings: Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.20
自引率
1.80%
发文量
21
审稿时长
6-12 weeks
期刊介绍: The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信